Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank

By afschroeder • September 13, 2026

Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG, Das A, Desai A, Dizman N, Drago D, Economides M, Geynisman DM, Griffith M, Hall T, Henske EP, Jonasch E, Khanna P, Kotecha RR, Luckenbaugh A, Maranchie JK, Master V, May AM, Motzer RJ, Ornstein MC, Ortiz MV, Pal SK, Perez JR, Rini B, Shapiro DD, Shuch BM, Singer AE, Singer EA, Stadler WM, Staehler M, Tannir NM, Vaishampayan UN, Xu W, Yip W, Zacharias NM, Voss MH. Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank. Urol Oncol. 2026 Sep 12:S1078-1439(26)00703-9. doi: 10.1016/j.urolonc.2026.07.035. Epub ahead of print. PMID: 42731937.

Tags: Hematology/Oncology, Publications

Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov[...]

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]

Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer

Li D, Garon EB. Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer. Clin Cancer Res. 2026 Sep 11. doi: 10.1158/1078-0432.CCR-26-2458. Epub ahead[...]